Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 72

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 72
---
 |      3.23 |     | 1/15/2033  |     |                                              |     |                             |
|                                |     | 1/2/2024      |     | 1/2/2024                     |     |                 — |     |              33,265 |     |    19.656 |     | 1/1/2034   |     |                                              |     |                             |
|                                |     | 1/2/2024      |     | 1/2/2024                     |     |                   |     |                     |     |           |     |            |     |                                       25,940 |     |                     464,585 |

(1) All equity awards are subject to accelerated vesting in the event of a termination without cause or resignation for good reason within 12 months following a change in control pursuant to the terms of the Named Executive Officers’ employment agreements.

(2) Options granted January 2, 2024 vest as to 25% of the total shares underlying the option on the first anniversary of the vesting commencement date and in equal annual installments over the following three years, subject to the holder’s continued employment with us through the applicable vesting date.

(3) On March 27, 2024, we held the March 2024 Special Meeting. At the March 2024 Special Meeting, our stockholders approved, and our Board subsequently implemented, a 1-for-30 reverse stock split of all then-outstanding shares of our Common Stock and the conversion of our Series A Preferred Stock into shares of Common Stock.

(4) All restricted stock units vest in four equal annual installments beginning on the first anniversary of the vesting commencement date, subject to employees continued employment with us through the applicable vesting date.

(5) Based on the closing price of our Common Stock of $17.91 on December 31, 2024, the last trading day of the fiscal year ended December 31, 2024.

<div align='center'>42</div>

(6) Dr. Kurtoglu was appointed Chief Operating Officer on November 13, 2023. On March 28, 2024, Dr. Kurtoglu’s title was changed to Chief Technology Officer.

(7) On November 13, 2023, we acquired Old Cartesian in the Merger. These options to purchase Old Cartesian common stock were converted into options to purchase shares of Series A Preferred Stock